Skip to main content
TipRanks
Go Ultimate75% OFF

Precigen (I5X) Q3 2026 Earnings Report

1 Followers

DE:I5X Q3 2026 EPS Results

Actual EPS
EUR 0.07
Consensus EPS
EUR 0.05
Beat/Miss
Beat by +EUR 0.02
One Year Ago EPS
-EUR 0.96

DE:I5X Q3 2026 Revenue Results

Actual Revenue
EUR 67.02M
Expected Revenue
EUR 64.68M
Beat/Miss
Beat by +EUR 2.35M
YoY Revenue Growth
+2437.58%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
DE:I5X Upcoming Earnings

Precigen's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:I5X Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-12.24%|
Earnings Call Sentiment|Positive

The call was strongly positive, supported by 37% sequential PAPZIMEOS revenue growth, profitability, positive operating cash flow ahead of guidance, broad payer coverage, rapid patient adoption and continued pipeline and platform expansion. The principal challenge discussed was the arrival of competition, while the company also carries $100 million of outstanding debt and associated interest expense.

Company Guidance

Precigen did not provide guidance for the fourth quarter, but said it feels very good about Q4 and its growth prospects, expects to continue converting a significant proportion of patients in the hub to treatment, and expects both hub and non-hub patients to be significant contributors to future growth; it continues to expect gross margins related to U.S. PAPZIMEOS sales to stabilize between the high 80 percentages and low 90 percentages going forward, expects to collect $96.5 million in trade accounts receivable over the 4 months following quarter end, does not currently anticipate a need to raise additional capital, and said it expects to have data and reporting from the redosing trial in 2020.

  • Strong PAPZIMEOS Revenue GrowthThird-quarter PAPZIMEOS net product revenue was $72.9 million, bringing launch-to-date revenue through the end of Q3 to approximately $151 million. Revenue increased from $53 million in Q2 to approximately $73 million in Q3, representing approximately $20 million or 37% sequential growth.
  • Profitability and Positive Cash Flow AchievedPrecigen reported net income of $35.8 million for Q3 and $47.9 million for the nine-month period ended September 30, 2026. The company generated positive cash flow from operating activities of $11.9 million in Q3, achieving this milestone ahead of prior guidance.
  • Improved Cash and Liquidity PositionCash, cash equivalents and investments increased from $38.7 million at the end of June to $51 million at the end of September. The company also had $96.5 million in trade accounts receivable, expected to be collected over the four months following quarter-end, and availability of an additional $25 million under its debt facility. Management said it does not currently anticipate a need to raise additional capital.
  • High Gross Margin ProfileThird-quarter cost of products and services was $6.5 million, resulting in gross profit of $67.6 million and a 91% gross margin. Management expects U.S. PAPZIMEOS gross margins to stabilize between the high 80 percentages and low 90 percentages going forward.
  • Reduced Research and Development CostsThird-quarter research and development costs were $6.6 million, a decrease of $5.7 million compared with the prior-year third quarter, primarily because PAPZIMEOS manufacturing costs had been expensed as R&D costs before FDA approval.
  • Broad Patient AdoptionMore than 500 patients have begun treatment with PAPZIMEOS and more than 300 have completed treatment. More than 600 patients are registered in the company’s hub, while institutions are also independently managing access and reimbursement through their own infrastructure.
  • Adoption Across the Full Disease SpectrumPatients with all surgical histories are receiving treatment, including those with 0, 1, 2, 3 or more than 3 surgeries in the prior 12 months. A significant proportion of treated patients had fewer than 3 surgeries in the preceding 12 months, demonstrating physician use of the broad approved label.
  • Broad Payer CoveragePrecigen secured coverage representing more than 315 million U.S. lives across commercial plans, Medicare and Medicaid, providing access to nearly 100% of insured lives nationwide. The permanent J-code became effective April 1, 2026.
  • Expanding Nationwide Treatment NetworkPAPZIMEOS is being supplied to treatment sites across the United States within 24 hours through the company’s established distribution network. Cold-chain storage and distribution requirements have not been an impediment to broad treatment access, and the company has expanded treatment across major academic centers, infusion centers and community practices.
  • Positive Commercial MomentumManagement reported steady growth in treatment-site activations, defined as sites ordering the drug, as well as positive lead indicators from hub activity, account activation, new accounts ordering and new patients being treated. The company said it feels very good about its Q4 growth prospects, although it is not providing fourth-quarter guidance.
  • Differentiated Clinical Efficacy and DurabilityThe pivotal PAPZIMEOS study demonstrated a 51% complete response rate, with 18 of 35 patients requiring no surgeries during the 12 months following treatment conclusion. The company stated that complete responses have remained durable for up to 5 years without additional treatment.
  • Favorable Safety and Administration ProfilePAPZIMEOS demonstrated no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 in the pivotal study. The therapy is administered through a defined regimen of subcutaneous injections without an external specialized device, and surgery during the dosing window is optional and at the physician’s discretion.
  • Full FDA Approval and Broad LabelPAPZIMEOS received full FDA approval in August 2025 without a requirement for a post-approval confirmatory clinical trial. The approved indication covers all adults with recurrent respiratory papillomatosis without requiring a minimum number of prior surgeries.
  • Established First-Line Market PositionManagement stated that leading RRP experts recognize and adopt PAPZIMEOS as the first-line standard of care for adults with RRP. The company has established physician relationships, payer access, reimbursement processes, treatment-site capabilities and operational experience across the country.
  • Significant Remaining U.S. Market OpportunityPrecigen estimates that approximately 27,000 adults live with RRP in the United States and said it remains in the early stages of realizing the potential of PAPZIMEOS.
  • Expansion Opportunities for PAPZIMEOSThe company is advancing three opportunities to expand PAPZIMEOS: a redosing study, pediatric development and global expansion. The redosing trial is established and enrolling to evaluate whether partial responders can become complete responders.
  • European Regulatory ProgressPAPZIMEOS’s marketing authorization application is under review by the European Medicines Agency, and the therapy has received orphan drug designation from the European Commission. Precigen is evaluating ex-U.S. partnership opportunities while also maintaining the capability to execute independently.
  • FDA Platform Technology DesignationIn September, the FDA granted platform technology designation to Precigen’s AdenoVerse platform. Management stated that the designation may allow the company to leverage manufacturing and preclinical knowledge generated through PAPZIMEOS, reduce duplicative development work and engage earlier and more frequently with the FDA.
  • Pipeline Advancement with PRGN-2009PRGN-2009 is being advanced as an AdenoVerse-based therapy designed to generate immune responses against HPV-16 and HPV-18, which are associated with head and neck and cervical cancers. The company plans to present new Phase II clinical data in HPV-associated head and neck cancers and provide a broader PRGN-2009 and AdenoVerse strategy update at its forthcoming R&D Day.

DE:I5X Earnings History

DE:I5X earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)0.10--0.06――
Nov 04, 20262026 (Q3)0.050.07-0.96107.55% (+1.03)
Aug 04, 20262026 (Q2)-0.010.05-0.08155.56% (+0.13)
May 13, 20262026 (Q1)-0.03-0.02-0.1688.89% (+0.14)
Mar 25, 20262025 (Q4)-0.08-0.06-0.075.41% (+0.00)
Nov 13, 20252025 (Q3)-0.08-0.96-0.08-1077.78% (-0.88)
Aug 12, 20252025 (Q2)-0.08-0.08-0.2160.87% (+0.13)
May 14, 20252025 (Q1)-0.12-0.16-0.09-80.00% (-0.07)
Mar 19, 20252024 (Q4)-0.05-0.07-0.1243.08% (+0.05)
Nov 14, 20242024 (Q3)-0.08-0.08-0.07-12.50% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed